Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes

Medicine and Dentistry

• Metabolite 100%
• Placebo 80%
• Urinary System 70%
• Dapagliflozin 60%
• Maturity Onset Diabetes of the Young 30%
• Plasma 30%
• Urine 20%
• Creatinine 20%
• Albumin 20%
• Sodium Glucose Cotransporter 2 Inhibitor 20%
• Mitochondrial Respiration 20%
• Excretion 10%
• Combination Therapy 10%
• Treatment Duration 10%
• ACE Inhibitor 10%
• Angiotensin Receptor Antagonist 10%
• Renal Protection 10%
• Enalapril Maleate 10%
• Therapeutic Procedure 10%
• Amaurosis 10%
• Gas Chromatography Mass Spectrometry 10%

Neuroscience

• Dapagliflozin 60%
• Placebo 40%
• Diabetes 30%
• Mitochondrial Respiration 20%
• Creatinine 20%
• Mitochondrial Function 20%
• Albumin 20%
• Sodium Glucose Cotransporter 2 20%
• Enzyme Inhibitor 10%
• Dipeptidyl Carboxypeptidase 10%
• Mass Spectrometry 10%
• Gas Chromatography 10%
• Angiotensin Receptor 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Dapagliflozin 60%
• Non Insulin Dependent Diabetes Mellitus 30%
• Albumin 20%
• Creatinine 20%
• Sodium Glucose Cotransporter 2 Inhibitor 20%
• Dipeptidyl Carboxypeptidase Inhibitor 10%
• Enalapril Maleate 10%
• Angiotensin Receptor Antagonist 10%
• Blindness 10%